Riliprubart Prefilled Pen (PFP)

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Polyneuropathy, Inflammatory Demyelinating, Chronic

Conditions

Polyneuropathy, Inflammatory Demyelinating, Chronic

Trial Timeline

Apr 1, 2025 → Oct 3, 2029

NCT ID

NCT06859099

About Riliprubart Prefilled Pen (PFP)

Riliprubart Prefilled Pen (PFP) is a phase 3 stage product being developed by Sanofi for Polyneuropathy, Inflammatory Demyelinating, Chronic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06859099. Target conditions include Polyneuropathy, Inflammatory Demyelinating, Chronic.

What happened to similar drugs?

5 of 17 similar drugs in Polyneuropathy, Inflammatory Demyelinating, Chronic were approved

Approved (5) Terminated (0) Active (12)

✅Qutenza + PregabalinAstellas PharmaApproved

✅tafamidis megluminePfizerApproved

✅Imipramine + Pregabalin + Imipramine, pregabalin + PlaceboPfizerApproved

✅IgPro10CSLApproved

✅Efgartigimod PH20 SCArgenxApproved

🔄tafamidisPfizerPhase 3

🔄riliprubart + Placebo + riliprubart + Placebo + IVIg + PlaceboSanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06859099	Phase 3	Recruiting	Apr 1, 2025	Oct 3, 2029	Polyneuropathy, Inflammatory Demyelinating, Chronic

Competing Products

20 competing products in Polyneuropathy, Inflammatory Demyelinating, Chronic

See all competitors

Product	Company	Stage	Hype Score
Qutenza + Pregabalin	Astellas Pharma	Approved	43
Ranirestat + Placebo	Eisai	Phase 2/3	38
KITE-363 + Fludarabine + Cyclophosphamide	Gilead Sciences	Phase 1	36
Fx-1006A + Placebo	Pfizer	Phase 2/3	38
tafamidis meglumine	Pfizer	Approved	43
Fx-1006A	Pfizer	Phase 2	35
Vyndaqel	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Phase 3	40
Imipramine + Pregabalin + Imipramine, pregabalin + Placebo	Pfizer	Approved	39
Fx-1006A	Pfizer	Phase 2/3	38
riliprubart + Placebo + riliprubart + Placebo + IVIg + Placebo	Sanofi	Phase 3	47
Intravenous Immunoglobulin	CSL	Pre-clinical	26
IgPro10	CSL	Approved	50
Immune Globulin Subcutaneous (Human)	CSL	Pre-clinical	26
IgPro20	CSL	Phase 3	40
Hizentra	CSL	Pre-clinical	33
10% liquid formulation of human immunoglobulin	CSL	Phase 3	40
IgPro20 (low dose) + Placebo + IgPro10 + IgPro20 (high dose)	CSL	Phase 3	40
levetiracetam	UCB	Phase 2	35
Rozanolixizumab	UCB	Pre-clinical	26